Download DEV - FL Cancer Brochure - MC7333

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
FLORIDA CAMPUS
RESEARCH
MAYO CLINIC
CANCER CENTER
MAYO CLINIC
CANCER CENTER
CONQUERING CANCER
Mayo Clinic is a worldwide
leader in cancer research
and care.
methods for cancer
prevention, diagnosis,
prognosis and therapy.
As a leading institution
funded by the National
Cancer Institute, Mayo
Clinic Cancer Center
conducts basic, clinic
and population science
research, translating
discoveries into improved
Mayo Clinic Cancer
Center is a single,
NCI-designated
comprehensive cancer
center with three
geographic locations,
treating nearly 20,000 new
cancer patients yearly.
THE FLORIDA CAMPUS BRINGS
TOGETHER THE LARGEST GROUP
OF CANCER SPECIALISTS IN THE
SOUTHEASTERN U.S.
Our campuses in
Minnesota, Florida and
Arizona collaborate on
research and treatment
to give patients advanced
care.
On the Florida campus
alone, more than
150 physicians and
investigators are involved
in cancer care and
research.
Our focus on clinical
care, education and
research allows us to be
innovative in all aspects
of cancer, from prevention
to the frontiers of highly
individualized treatment.
Mayo Clinic’s Florida
campus also is a leader in
blood cancers and bone
marrow transplants in the
Southeastern U.S.
RESEARCH THAT ADVANCES CARE
The C.V. and Elsie Griffin
Cancer Research Building
on the Florida campus
houses 15 dedicated
cancer laboratories. Our
teams, led by national
and international leaders
in cancer research,
study all stages of
tumor progression, from
early tumor growth to
metastasis.
Research is integrated
with the three-site Mayo
Clinic Cancer Center
and Mayo’s five nationallydesignated Specialized
Programs of Research
Excellence (SPOREs).
2
Our cancer researchers
also collaborate with
the Mayo Clinic Center
for Individualized
Medicine, which focuses
on providing highly
personalized care based
on an individual’s genome.
All faculty of the
Department of Cancer
Biology on the Florida
campus also are full
members of the Mayo
Graduate School, actively
involved in teaching
and mentoring the next
generation of cancer
researchers.
F L O R I D A C A M P U S R E S E A R C H • M AYO C L I N I C C A N C E R C E N T E R
C.V. and Elsie Griffin Cancer Research Building
Cancer Research on the Florida Campus
> Integral part of Mayo’s NCI-designated comprehensive
cancer center
> Research teams led by 15 cancer researchers
> Studies in breast, pancreatic, thyroid, prostate, brain,
ovarian, lung, skin, kidney and liver cancers
> More than 200 clinical trials
MAYO CLINIC
CANCER CENTER
LEADING NEW KNOWLEDGE
Mayo Clinic focuses on advancing real improvements in patient care.
Recent discoveries by the Florida campus team include:
A protein that is overly active in nearly 85
percent of kidney cancer cases in the U.S., and
an experimental drug that blocks the protein’s
activity, significantly reducing tumor growth
in animal models. This also is a potential new
direction for treating lung, stomach, breast,
prostate, ovary and colon cancers.
A molecular mutation in various forms of
breast cancer that may provide a new way to
identify tumor types and offer new strategies to
treat them.
A gene that promotes the development of
non-small cell lung cancer, the leading cause
of U.S. cancer deaths. Shutting down the gene
renders the lung cancer stem cells unable to
develop tumors. This gene may play a role in other
cancers, as well.
A new target to improve treatment of
pancreatic cancer. Researchers decoded a
molecular pathway that is switched “on” at all
times, promoting accelerated growth of pancreatic
tumors. This discovery revealed ways to disable
the pathway. This includes the drug bortezomib,
which offers new hope for treating patients with
pancreatic cancer.
Stopping the lethal spread of the aggressive
brain cancer glioblastoma multiforme by
pairing the drug bevacizumab with the cancer
drug dasatinib, which already is approved for use
in blood cancers. Mayo Clinic has conducted a
phase I clinical trial to determine drug dosage,
and is now conducting a randomized phase II
study of 100 patients to prove efficacy.
Decoding the pathway that regulates blood
vessel “leakiness” and promotes cancer growth
and spread. Several experimental agents might
help reverse this process.
“OUR GOAL IS TO GENERATE BREAKTHROUGHS THAT
WILL LEAD TO NEW TREATMENTS FOR PATIENTS.”
Panagiotis Z. Anastasiadis, Ph.D.
Chair, Department of Cancer Biology, Mayo Clinic in Florida
Co-Director, Cell Biology Program, Mayo Clinic Cancer Center
Associate Professor of Biochemistry/Molecular Biology, Mayo College of Medicine
F L O R I D A C A M P U S R E S E A R C H • M AYO C L I N I C C A N C E R C E N T E R
3
MAYO CLINIC
CANCER CENTER
JOIN US IN CONQUERING CANCER
Your philanthropic support is vital to conduct the
kind of groundbreaking research and care that has
earned Mayo Clinic an international reputation for
excellence in integrated patient care, research
and education.
Your support really does make a difference.
For example, the Mayo Clinic Breast Cancer
Translational Genomics Program was launched on
the Florida campus with philanthropic funding.
The program focuses on biomarkers and pathways that
drive breast cancer. We are developing personalized
therapies for patients, with the support of generous
benefactors like you.
THANK YOU FOR CONSIDERING
PARTNERING WITH MAYO CLINIC
CANCER CENTER TO PROVIDE
EXACTLY THE CARE EACH
PERSON NEEDS.
mayoclinic.org/mayo-clinic-cancer-center
MC7333